Ethionamide
- Atc Codes:J04AD03
- CAS Codes:536-33-4
- PHARMGKB ID:536-33-4
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Greece: Trecator.
North America
USA: Trecator.
Asia
Japan: Tubermin.
Drug combinations
Chemistry
Ethionamide: C~8~H~10~N~2~S. Mw: 166.24. (1) 4-Pyridinecarbothioamide, 2-ethyl-; (2) 2-Ethylthioisonicotinamide. CAS-536-33-4 (1961).
Pharmacologic Category
Antimycobacterials; Antituberculosis Agents. (ATC-Code: J04AD03).
Mechanism of action
A synthetic, isonicotinic acid-derivative antituberculosis agent. Exact mechanism of action of ethionamide not fully elucidated, but drug appears to inhibit peptide synthesis in susceptible organisms.
Therapeutic use
Usually used in conjunction with other antituberculosis agents in treatment of drug-resistant tuberculosis caused by Mycobacterium tuberculosis known or presumed to be susceptible to the drug, especially when isoniazid and/or rifampin cannot be used due to resistance and/or intolerance.
Pregnancy and lactiation implications
The drug should not be used during pregnancy as it crosses the placenta and is teratogenic in animals. Should be administered to nursing mothers only if benefits of therapy outweigh potential risks to the infant.
Unlabeled use
Contraindications
Hypersensitivity to ethionamide or any component of the formulation. Severe hepatic impairment.
Warnings and precautions
Hepatitis (with or without jaundice) reported. Transient increases in serum bilirubin, AST, and ALT have occurred. Use caution in diabetic patients. Psychotic disturbances (including mental depression), drowsiness, dizziness, restlessness, headache, and postural hypotension reported. Hypothyroidism (with or without goiter) reported. Must be given in conjunction with other antituberculosis agents. Manufacturer states the drug should not be used in children <12 years of age except when tuberculosis is resistant to first-line therapy. Use caution in hepatic disease (contraindicated in severe hepatic impairment).